

**APA030Hu03 100µg**  
**Active Factor Related Apoptosis (FAS)**  
**Organism Species: Homo sapiens (Human)**  
***Instruction manual***

FOR IN VITRO USE AND RESEARCH USE ONLY  
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

---

---

1st Edition (Apr, 2016)

## **[ PROPERTIES ]**

**Source:** Prokaryotic expression.

**Host:** *E. coli*

**Residues:** Ser22~Ser172

**Tags:** Two N-terminal Tags, His-tag and MBP-tag

**Purity:** >95%

**Buffer Formulation:** 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

**Applications:** Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

**Predicted isoelectric point:** 5.8

**Predicted Molecular Mass:** 66.9kDa

**Accurate Molecular Mass:** 66kDa as determined by SDS-PAGE reducing conditions.

## **[ USAGE ]**

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

## **[ STORAGE AND STABILITY ]**

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.


**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

## **[ SEQUENCE ]**

```
SVNAQVTDI NSKGLELRKT VTTVETQNLE  
GLHHDGQFCH KPCPPGERKA RDCTVNGDEP DCVPCQEGKE YTDKAHFSSK  
CRRRCRLCDEG HGLEVEINCT RTQNTKCRCK PNFFCNSTVC EHC DPCTKCE  
HGIIECTLT SNTKCKEEGS RS
```


## **[ ACTIVITY ]**

FAS (Tumor necrosis factor receptor superfamily member 6) belongs to the tumor necrosis factor receptor superfamily. FAS contains a death domain, which has been shown to play a central role in the physiological regulation of programmed cell death. A binding ELISA assay was conducted to detect the association of FAS with TNF $\alpha$ . Briefly, FAS were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100 $\mu$ L FAS were then transferred to TNF $\alpha$ -coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-FAS pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50 $\mu$ L stop solution to the wells and read at 450nm immediately. The binding activity of FAS and TNF $\alpha$  was shown in Figure 1, and this effect was in a dose dependent manner.




**Figure 1. The binding activity of FAS with TNFα.**

## [ IDENTIFICATION ]




**Figure 2. Gene Sequencing (extract)**



**Figure 3. SDS-PAGE**

**Sample: Active recombinant FAS, Human**



**Figure 4. Western Blot**

**Sample: Recombinant FAS, Human;**

**Antibody: Rabbit Anti-Human FAS Ab (PAA030Hu03)**